Search | Clinical Trials Finder

Conditions: Acute Burns
Interventions: Magellan®, Placebo Saline Gel and Usual and Customary Standard of Care; Device · Other
Lead sponsor: Arteriocyte, Inc.; Industry
Eligibility: 18 Years to 86 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Sacramento, California • Washington D.C., District of Columbia • Salt Lake City, Utah

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 2
States / cities: Los Angeles, California • New Hyde Park, New York

Conditions: Melanoma (Skin)
Interventions: aldesleukin, gp100 antigen, tyrosinase peptide; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 2
States / cities: Durham, North Carolina • Charlottesville, Virginia

Conditions: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor
Interventions: Dendritic cell immunotherapy; Drug
Lead sponsor: Northwest Biotherapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Castro Valley, California + 56 more

Conditions: Melanoma (Skin)
Interventions: autologous dendritic cell-tumor fusion vaccine, gp100 antigen, therapeutic autologous dendritic cells; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: filgrastim, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody B3; Biological · Procedure · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer
Interventions: carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support; Drug · Procedure
Lead sponsor: Loyola University; Other
Eligibility: Up to 64 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2005
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Osteoarthritis, Hip
Interventions: Autologous Adipose Derived Mesenchymal Stromal Cells; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Leukemia
Interventions: filgrastim; Biological
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Stroke, Stroke, Ischemic
Interventions: HB-adMSCs; Biological
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Fistula in Ano, Crohn Disease
Interventions: MSC-AFP; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infection, HIV Infections
Interventions: SB-728-T; Genetic
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 6 more

Conditions: Multiple Myeloma, Stem Cell Transplant Complications
Interventions: Tai Chi Easy; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Tucson, Arizona • Jacksonville, Florida

Conditions: Non-Hodgkin's Lymphoma
Interventions: Carmustine, Etoposide, Cytarabine, Melphalan, Pegfilgrastim, 19-28z T CELLS, Autologous Stem Cell Transplantation; Drug · Biological · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Photoaging
Interventions: Harvest PRP Separation System, Sterile Saline injection; Device · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: falimarev, inalimarev, sargramostim, therapeutic autologous dendritic cells; Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Durham, North Carolina + 3 more

Conditions: Inflammatory Bowel Diseases
Interventions: Lipoaspiration, AD-cSVF, Normal Saline IV; Procedure
Lead sponsor: Healeon Medical Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Stevensville, Montana

Conditions: Breast Cancer
Interventions: aldesleukin, recombinant interferon gamma, carboplatin, cyclophosphamide, cyclosporine, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Autologous Stem Cell Transplantation
Interventions: G-CSF plus plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Pancreatic Fistula, Distal Pancreatectomy Complications, Falciform Patch Pancreatic Closure, Fibrin Glue Pancreatic Closure
Interventions: Falciform patch and fibrin glue application, standard pancreatic closure; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Cleveland, Ohio • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Autologous HIV-1 ApB DC Vaccine; Biological
Lead sponsor: Sharon Riddler; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Extraocular Retinoblastoma
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Radiation Therapy, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Search by objective public record fields.

Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer

Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer

Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA

The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis

G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission

Individual Patient Expanded Access IND for the Treatment of Stroke

Pediatric MSC-AFP Sub-study for Crohn's Fistula

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Effect of Platelet Rich Plasma on Photoaged Skin

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

An Evaluation of a New Technique Utilizing a Biologic Glue and Tissue Patch to Seal the Cut Edge of the Pancreas Following Removal of the Tail of the Pancreas

Autologous Dendritic Cell Vaccine in HIV1 Infection

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma